Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 16 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 11712460

    Methods of treating chronic disorders with complement inhibitors

    Apellis Pharmaceuticals, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  2. US 11708364

    Azaindole derivatives and their use as ERK kinase inhibitors

    AGV Discovery · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  3. US 11708329

    Inhibitors of the WNT/beta-catenin pathway

    The Regents of the University of California · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  4. US 11708333

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  5. US 11708332

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  6. US 11708347

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  7. US 11702400

    Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors

    Medshine Discovery Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  8. US 11702415

    Crystalline hydrate of a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  9. US 11701361

    p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens

    The Regents of the University of Colorado · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  10. US 11702411

    Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  11. US 11702389

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  12. US 11701354

    Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors

    Relay Therapeutics, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  13. US 11697648

    Fused pyrimidine pyridinone compounds as JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jul 11, 2023 · Expires Jul 6, 2043

    granted
  14. US 11690850

    Inhibitors of receptor interacting protein kinase I for the treatment of disease

    The Board of Regents of the University of Texas System · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  15. US 11691987

    Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  16. US 11690915

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  17. US 11691974

    3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors

    Medshine Discovery Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  18. US 11691989

    Macrocyclic indoles as Mcl-1 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  19. US 11685744

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  20. US 11685775

    Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

    The Regents of the University of California · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  21. US 11685721

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  22. US 11685749

    C26-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  23. US 11679112

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted
  24. US 11679101

    Anhydrous compositions of mTOR inhibitors and methods of use

    PALVELLA THERAPEUTICS, INC. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted